Go to main content | Go to main menu | Go to search

Project information
NGS-PTL - Next Generation Sequencing platform for targeted Personalized Therapy of Leukemia (NGS-PTL)

Information

This project doesn't include Faculty of Arts. It includes Central European Institute of Technology. Official project website can be found on muni.cz.
Investor logo
Project Identification
306242
Project Period
11/2012 - 10/2015
Investor / Pogramme / Project type
European Union
  • 7th Specific RTD Programme
  • Cooperation
MU Faculty or unit
Central European Institute of Technology
Cooperating Organization
Institute of Postgraduate Education in Medicine Prague
Universität Ulm
Universita di Bologna
  • Responsible person prof. Giovanni Martinelli

Hematological diseases are highly heterogeneous malignancies in the matter of the molecular mechanisms related to their development and progression. A considerable heterogeneity can be further observed within the same hematological disease at the inter-individual level, being reflected by different clinical outcomes and responses to treatment in different patients. Nowadays the advent of high-throughput sequencing (HTS) technologies that are revolutionizing genomics and transcriptomics by providing a single base resolution tool for a unified deep analysis of diseases complexity allows a fast and cost-efficient fine-scale assessment of the genetic/genomic variability hidden within cohorts of patients affected by the same leukemia. That being so, by potentially highlighting inter-individual differences that may play a role in the differential success of diverse therapeutic interventions, they promise to be crucial for selecting the most appropriate medical treatments. This project aims at developing a European Hematological/HTS platform of scientists for improving outcomes for therapeutic interventions on acute and chronic leukemias and at develop strategies to personalize treatments and tailor therapies to different stratified groups of leukemia patients, with the goal of optimizing their efficacy and safety through a deeper and deeper understanding of the influence of genetic/genomic alterations on leukemias pathogenesis and treatment response (i.e. “personalized therapy”). Moreover, the final aim will be the identification of novel prognostic biomarkers for acute and chronic leukemias, as well as of molecular biomarkers and/or genomic profiles for the assessment of minimal residual disease. The originality of this project is to perform systematic deep genomic/transcriptomic studies on well-clinically-characterized leukemia patients, by exploiting HTS technologies able to quickly produce data with a good cost-effectiveness and an unprecedented resolution.

Publications

Total number of publications: 17

2016

2015

Previous 1 2 Next

You are running an old browser version. We recommend updating your browser to its latest version.